News & Events
Second EVIDENT paper published in Nature
On 3 February 2016 a second EVIDENT paper has been published online in the Journal Nature. In the publication titled “Real-time, portable genome sequencing for Ebola surveillance” the authors devise a genomic surveillance system that utilizes a novel nanopore DNA sequencing instrument. In April 2015 this system was transported in standard airline luggage to Guinea and used for real-time genomic...
Final stretch for the EVIDENT consortium
From 21 to 22 January 2016 the EVIDENT consortium came together for its 2nd Progress Meeting at the St. Hilda’s College in Oxford (UK) which provided a dignified setting for the EVIDENT group.
8th IMI 2 Call: Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks
The preliminary topics for future calls for proposals to be launched in late 2015 and early 2016 have been published on the IMI 2 website. The 8th call addresses the Ebola+ Programm: Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks IMI 2 8th call for proposal, indicative call text:...
Presentation by Prof. Miles Carroll at the Robert Koch-Institute
On 2 December 2015 Prof. Miles Carroll of Public-Health England spoke at the EVIDENT partner institution Robert Koch-Institute in Berlin (Germany). The presentation entitled "Ebola: Response, sequencing, clinical trials and survivors" included information and findings that have been obtained within the EVIDENT project. In EVIDENT, Public Health England continues the studies on the...
EVIDENT: current activities
Hoping that we are witnessing the end of the EVD outbreak we keep evaluating putative biomarkers of outcome in the BSL4 laboratory in Hamburg. Our current efforts are focused on the analysis of soluble biomarkers in plasma samples, immune markers of virus transmission, and multivariate analysis to find signatures of fatal EVD. A novelty has been the initiation of genetic studies that should lead...
Ongoing activities in EVIDENT
Despite the fact that the ongoing outbreak has generated a significant amount of research data, one of the poorly known aspects of EVD is the mechanism/s of human-to-human transmission. EVIDENT teams are looking into transmission 'signatures' by looking at 'prints' left by the virus on the host immune systems. This strategy, combined with epidemiological data from WHO will hopefully help to track...
EBOV sequences generated in Sierra Leone
The EMLab/EVIDENT consortium, University of Cambridge, and Wellcome Trust Sanger Institute are releasing EBOV sequences generated in Sierra Leone to support the public health response as well as the development and evaluation of EVD vaccines, therapeutics, and diagnostics. Please feel free to download, use, and analyse this data.
Latest EBOV sequences generated with MinION technology in real-time in Guinea available
The EVIDENT consortium is releasing the latest EBOV sequences generated with MinION technology in real-time in Guinea to support the public health response as well as the development and evaluation of EVD vaccines, therapeutics, and diagnostics. Please feel free to download, use, and analyse this data.